Early Research and Development (1990s)
Sapropterin, also known as 6R-tetrahydrobiopterin (6R-BH4), has its roots in the study of hyperphenylalaninemia, a genetic disorder caused by the deficiency of the enzyme phenylalanine hydroxylase (PAH). Researchers at Children's Hospital Corporation, Boston, and Harvard Medical School began exploring the potential of BH4 as a treatment in the 1990s [1].
Patented Technology (1997)
The Children's Hospital Corporation patented the use of BH4 for the treatment of PAH deficiency in 1997 [2]. This marked a significant step forward in the development of sapropterin as a therapeutic agent.
Clinical Trials (2000s)
In the early 2000s, a series of clinical trials demonstrated the efficacy and safety of BH4 in reducing blood phenylalanine levels in PAH-deficient patients. These trials were conducted at various sites in the United States and abroad, including the Children's Hospital Corporation and Harvard Medical School [3].
Approval and Launch (2007)
Sapropterin was approved by the US FDA in January 2007 for the treatment of PAH deficiency in pediatric patients, under the brand name Kuvan. The approval was based on the results of the Phase III clinical trials, which showed significant reductions in blood phenylalanine levels and improvements in phenylalanine-related symptoms [4].
Continued Research and Development
Since its approval, sapropterin has continued to be the subject of ongoing research and development efforts. Studies have investigated its use in various patient populations, including adults and those with other genetic disorders. Additionally, researchers have explored potential uses for sapropterin beyond its approved indication, including as a potential treatment for other metabolic disorders [5].
DrugPatentWatch.com: For more information on the patent landscape for sapropterin, please visit DrugPatentWatch.com [6].
Sources:
[1] Kure, S., et al. " Tetrahydrobiopterin-responsive phenylketonuria: diagnostic tests, biochemical and molecular basis." Journal of Inherited Metabolic Disease 27.1 (2004): 3-11.
[2] United States Patent 5,696,257, "Methods for treating phenylketonuria using tetrahydrobiopterin".
[3] Kohen, R. et al. " Tetrahydrobiopterin responsive phenylketonuria: clinical and biochemical features of a large patient population." Molecular Genetics and Metabolism 91.1 (2007): 34-41.
[4] FDA Approves Kuvan for Treatment of Phenylketonuria, January 2007.
[5] Sapropterin dihydrochloride (Kuvan): drug information, 2023.
[6] DrugPatentWatch.com: Sapropterin (6R-Tetrahydrobiopterin) patents.